TORONTO, July 10 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX: SDI) today announced that it has entered into a exclusive distribution agreement in Russia with BB Medical for Spectral's Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxin. Under the terms of the agreement, BB Medical will market and sell EAA(TM) throughout the Russian Federation.
"BB Medical is a leading distributor of medical technologies in Russia. Their significant market reach in this region will help to strengthen our presence in yet another geographic territory - a key component in the global commercialization strategy for our EAA(TM) product," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "Our distribution agreement with BB Medical in Russia is expected to be the first of several distribution agreements in new geographic territories. Ultimately, these alliances will drive the adoption of our unique product globally, both as a stand-alone product, and also in combination with therapeutics for the diagnosis, treatment and monitoring of patients with endotoxemia."
Spectral's distribution agreement with BB Medical is a result of the Company's expanded collaboration agreement with Toray Medical that was announced in May. Through this expanded agreement with Toray, Spectral may now access Toray's distributors in other geographic territories including China, India and Canada for the sales and promotion of EAA(TM).
About Spectral Diagnostics
Spectral is a leader in the battle against sepsis. Spectral's lead
product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared
assay for the measurement of endotoxin. With the growing awareness for the
role of endotoxemia in sepsis and the increasing number of therapies being
developed for this indication, Spectral is well-positioned to drive the
adoption of the EAA(TM), which can be used to identify patients, enable
therapeutics and monitor trea
|SOURCE Spectral Diagnostics Inc.|
Copyright©2008 PR Newswire.
All rights reserved